Ticarcillin Sodium and Clavulanate Potassium for Injection

The main ingredients of Ticarcillin Sodium Clavulanate Potassium for Injection (15:1) are Ticarcillin Sodium and Clavulanate Potassium. Ticarcillin is a broad-spectrum bactericidal agent of the penicillin class, while clavulanic acid is an irreversible, highly effective beta-lactamase inhibitor. Many Gram-positive bacteria (G) and Gram-negative bacteria (G-) can produce beta-lactamases, which can destroy penicillins before they act on pathogens. Clavulanic acid destroys the bacterial defense barrier by blocking beta-lactamase and restores ticarcillin sensitivity. Potassium clavulanate has little antibacterial effect alone, but when combined with Ticarcillin, it becomes an antibiotic with a broad-spectrum bactericidal effect, which is suitable for the empirical treatment of a wide range of bacterial infectious diseases. Ticarcillin Sodium and Clavulanate Potassium for Injection (15:1) is an antibiotic with a broad-spectrum bactericidal effect. Its in vitro antibacterial spectrum is: Gram-positive bacteria Aerobic bacteria: Staphylococcus (including Staphylococcus aureus and Staphylococcus epidermidis), Streptococcus (including fecal Streptococcus) Anaerobic bacteria: Peptococcus, Peptostreptococcus, Clostridium, Eubacterium Gram-negative bacteria Aerobic bacteria: Escherichia coli, Haemophilus (including Haemophilus influenzae), Branhamella catarrhalis, Klebsiella (including Klebsiella pneumoniae), Enterobacter, Proteus (including indole-positive bacteria), Providencia stutzeri, Pseudomonas (including Pseudomonas aeruginosa), Serratia (including Serratia marcescens), Citrobacter, Acinetobacter calcoaceticus, Narsella enterocolitica Anaerobic bacteria: Bacteroides (including Bacteroides fragilis), Fusobacterium, Veillonella

This product is a compound preparation, each vial containing 3.0g of ticarcillin and 0.2g of clavulanic acid.

This product is suitable for the treatment of various bacterial infections, and its scope of action is wide. The main indications are as follows: severe infections: sepsis, infections in special populations (secondary to immune system suppression or damage), bacteremia, peritonitis, intra-abdominal abscesses, respiratory tract infections, postoperative infections, severe or complicated urinary tract infections (such as pyelonephritis), bone and joint infections, skin and soft tissue infections, ear, nose and throat infections. This product has a synergistic effect when used in combination with aminoglycoside antibiotics to treat a variety of infections (including Pseudomonas aeruginosa infections), especially in the treatment of critical infections and infections in patients with systemic dysfunction. When this product is used in combination with aminoglycoside antibiotics, the two drugs should be administered separately.

Dosage: Common dosage for adults (including the elderly): 1.6-3.2 g every 6-8 hours, depending on body weight. Maximum dosage: 3.2 g every 4 hours. Recommended dosage for patients with renal insufficiency: 3.2 g every 8 hours for mild impairment (creatinine clearance 30 ml/min); 1.6 g every 8 hours for moderate impairment (creatinine clearance 10-13 ml/min); 1.6 g every 12 hours for severe impairment (creatinine clearance < 10 ml/min). Children: Common dosage: 80 mg/kg body weight every 6-8 hours. Dosage for neonates: 80 mg/kg body weight every 12 hours, which can then be increased to every 8 hours. Dosage for children with renal insufficiency: must be adjusted according to the recommended dosage for adult patients with renal insufficiency. Usage: This product can be administered intermittently through intravenous drip; this product is not for intramuscular injection. Intravenous drip: This product needs to be prepared into a solution with water for injection or glucose injection (≤5%) before use. Dissolve this product (3.2g) in 100ml water for injection or 100-150ml5% glucose injection before use. A single intravenous infusion of ticarcillin sodium-clavulanate potassium for injection must be completed within 30-40 minutes. Avoid long infusion time to cause blood drug concentration below the therapeutic level. Heat is generated when ticarcillin sodium-clavulanate potassium for injection is dissolved, and the prepared solution is usually light gray-yellow. The prepared intravenous solution of ticarcillin sodium-clavulanate potassium for injection must be used immediately. The same package of ticarcillin sodium-clavulanate potassium for injection cannot be used multiple times, and the remaining residual solution must be discarded; this product cannot be injected intramuscularly.

1. Allergic reactions: If an allergic reaction occurs, the drug should be stopped immediately. Rash, herpes, urticaria and other allergic reactions may occur. 2. Gastrointestinal reactions: Nausea, vomiting and diarrhea, rarely pseudomembranous colitis. 3. Changes in liver function: Increased AST and/or ALT, and individual reports of hepatitis and cholestatic jaundice. The above changes may also occur in the use of other penicillins and cephalosporin antibiotics. 4. Changes in renal function: Rare hypokalemia. 5. Central nervous system reactions: Rare convulsions, mainly occurring in patients with renal insufficiency or high-dose use of this product. 6. Changes in the blood system: Thrombocytopenia, leukopenia and bleeding. 7. Local reactions: Thrombophlebitis at the site of intravenous injection.

It is contraindicated for patients with a history of allergy to β-lactam antibiotics (such as penicillin, cephalosporin).

Probenecid can reduce the renal tubular secretion of ticarcillin, thereby delaying the renal excretion of ticarcillin, but does not affect the renal excretion of clavulanic acid.

Sealed and stored in a cool place

1.6g (C15H16N2O6S21.5g and C8H9NO50.1g)

Hainan Meimei Xilin Biopharmaceutical Co., Ltd.

• Founded in:

  2007-12-24

• Address:

  Factory Building No. 26, Guilinyang Development Zone, Meilan District, Haikou City

• Tax NO.:

  91460000798744593P

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view